Abstracts tagged "autoimmune diseases"

Abstract Number: 2155 • 2019 ACR/ARP Annual Meeting
The Spectrum of Interstitial Lung Disease Associated with Autoimmune Diseases: Data of a 3-Year-Prospective Study from a Referral Center of Lung Transplantation
Sara Remuzgo-Martínez¹, Diana Prieto-Peña ², Mónica Calderón-Goercke ², Victor Manuel Mora Cuesta ³, David Iturbe Fernández ¹, Sonia M. Fernández Rozas ³, Jose Manuel Cifrian Martínez ³ and Miguel Angel González-Gay ⁴, ¹Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, IDIVAL, Santander, Spain, Santander, Spain, ²Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, IDIVAL; and Rheumatology Department, Hospital Universitario Marqués de Valdecilla, Santander, Spain, Santander, Spain, ³Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, IDIVAL; and Pneumology Department, Hospital Universitario Marqués de Valdecilla, Santander, Spain, Santander, Spain, ⁴Universidad de Cantabria and IDIVAL, Hospital Universitario Marqués de Valdecilla, Santander, Spain
Background/Purpose: Interstitial lung disease (ILD) occurs in approximately 15% of patients with autoimmune diseases (AD) [1]. Its presence is associated with an increased risk of…
Abstract Number: 1077 • 2019 ACR/ARP Annual Meeting
Mediation of Adverse Pregnancy Outcomes in Autoimmune Conditions by Pregnancy Complications
Christina Chambers¹, Gretchen Bandoli ², Namrata Singh ³, Jennifer Strouse ⁴, Rebecca Baer ⁵, Brittney Donovan ⁶, Sky Feuer ⁷, Nichole Nidey ⁶, Kelli Ryckman ⁶ and Laura Jelliffe-Pawlowski ⁷, ¹University of California San Diego, La Jolla, ²University of California, San Diego, La Jolla, ³University of Iowa, Iowa City, ⁴University of Iowa Hospitals and Clinics, Iowa City, ⁵UCSD, La Jolla, ⁶UIOWA, Iowa City, ⁷UCSF, San Francisco
Background/Purpose: Autoimmune conditions are associated with an increased risk of adverse pregnancy complications and outcomes, suggesting that pregnancy complications may mediate the excess risk. We…
Abstract Number: 2296 • 2019 ACR/ARP Annual Meeting
Assisted Reproductive Technology in Patients with Inflammatory and Autoimmune Rheumatic Disease
Elisa Trujillo¹ and Erika Padrón ¹, ¹Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain
Background/Purpose: Women with chronic inflammatory and autoimmune diseases increasingly solicit assisted reproductive techniques (ART) due to infertility, but there is little information about success rates…
Abstract Number: 1270 • 2019 ACR/ARP Annual Meeting
Effectiveness and Safety of Off-label Use of Tocilizumab in Refractory Autoimmune Diseases: A Multicenter Study
Martin Michaud¹, Thomas Sene ², Pascal Chazerain ², Geoffrey Urbanski ³, Frederique Retornaz ⁴, Boris Bienvenu ⁵, Laurent Chiche ⁴, Florian Catros ⁶, Laurent Sailler ⁷, Laurent Alric ⁸, Jean Thomas Giraud ⁹, Léo Caudrelier ¹⁰, Slim Lassoued ¹⁰, Sophie Ancellin ⁶, Olivier Lidove ² and Francis Gaches ⁶, ¹Joseph Ducuing Hospital, Toulouse, France, ²Hôpital Croix Saint Simon, Paris, France, ³CHU Angers, Angers, France, ⁴Hôpital Européen, Marseille, France, ⁵Hôpital Saint Joseph, Marseille, France, ⁶Hôpital Joseph Ducuing, Toulouse, France, ⁷University Hospital of Toulouse, Toulouse, France, ⁸CHU Toulouse, Toulouse, France, ⁹Hôpital de Tarbes, Tarbes, France, ¹⁰Hôpital de Cahors, Cahors, France
Background/Purpose: There is increasing evidence of Tocilizumab (TCZ) efficacy in refractory auto-immune diseases. The present study aimed at evaluating the real-world experience of using TCZ…
Abstract Number: 2736 • 2019 ACR/ARP Annual Meeting
Mucosal-associated Invariant T Cells Can Be Therapeutically Targeted in Lupus
Goh Murayama¹, Asako Chiba ², Tomohiro Mizuno ³, Atsushi Nomura ², Taiga Kuga ⁴, HIrofumi Amano ⁴, Ken Yamaji ⁴, Naoto Tamura ⁴ and Sachiko Miyake ², ¹Department of Internal Medicine and Rhumatology, Juntendo University School of Medicine, Tokyo, Japan, ²Department of Immunology, Juntendo University School of Medicine, Tokyo, Japan, ³Department of Immunlogy, Juntendo University School of Medicine, Tokyo, Japan, ⁴Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan
Background/Purpose: Mucosal-associated invariant T (MAIT) cells are innate T cells that are restricted by the nonpolymorphic MHC-related molecule-1 (MR1) and express a semi-invariant TCRα chain:…
Abstract Number: 1295 • 2019 ACR/ARP Annual Meeting
Otoferlin Is Increased in Muscle and PBMCs from Untreated Children with Juvenile Dermatomyositis: Possible Association with Decreased Circulating Natural Killer Cells
Lauren Pachman¹, Wil Marin ², Gabrielle Morgan ¹, Megan L. Curran ³, Kaveh Ardalan ⁴, Chiang-Ching Huang ⁵ and Eli Roberson ⁶, ¹Northwestern University, Chicago, ²Ann and Robert H. Lurie Childrens Hospital of Chicago, Chicago, IL, ³University of Colorado, Aurora, CO, ⁴Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, ⁵University of Milwaukee, Milwaukee, WI, ⁶Washington University at St.Louis, St.Louis, MO
Background/Purpose: Juvenile Dermatomyositis (JDM) is a rare inflammatory myopathy in which the immunoregulatory control is not well understood. Collaboration with A.R. French, MD/PhD, documented the…
Abstract Number: 2741 • 2019 ACR/ARP Annual Meeting
Integration of Single Cells from Inflammatory Disease Tissues Reveals Common and Unique Pathogenic Cell States
Fan Zhang¹, Joseph Mears ¹, ilya Korsunsky ¹, Kevin Wei ², Anna Helena Jonsson ², Deepak Rao ¹, Edy Kim ³, Laura Donlin ⁴, Jill Buyon ⁵, Michelle Petri ⁶, Chaim Putterman ⁷, Thomas Tuschl ⁸, Nir Hacohen ⁹, Betty Diamond ¹⁰, Michael Brenner ¹¹ and Soumya Raychaudhuri ¹, ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ³Brigham and Women's Hospital, Boton, MA, ⁴Hospital For Special Surgery, New York, NY, ⁵New York University School of Medicine, New York, NY, ⁶Johns Hopkins University School of Medicine, Baltimore, MD, ⁷Albert Einstein College of Medicine, New York, NY, ⁸Rockefeller Research Laboratories, New York, ⁹Broad Institute, Cambridge, ¹⁰Feinstein Institutes for Medical Research, Manhasset, ¹¹Brigham and Women’s Hospital:, Boston
Background/Purpose: Different autoimmune diseases can co-exist in an individual and share similar genetic associations, autoimmune signaling pathways, and clinical manifestations. However, autoimmune diseases present varied…
Abstract Number: 1339 • 2019 ACR/ARP Annual Meeting
Risk of Immunotherapy Related Toxicity in Patients with Rheumatoid Arthritis
Elizaveta Efuni ¹, Samuel Cytryn ², Patrick Boland ² and Sabina Sandigursky³, ¹New York University School of Medicine, New York, NY, ²NYU Langone Health, New York, ³NYU Langone Health, New York, NY
Background/Purpose: Immune checkpoint inhibitors (ICIs) have changed the therapeutic landscape in oncology leading to cures in some cancer types. However, patients with pre-existing autoimmune diseases…
Abstract Number: 2780 • 2019 ACR/ARP Annual Meeting
Identification of SLE Subgroups at Risk for Poor Outcomes After Hydroxychloroquine Taper or Discontinuation
Celline C. Almeida-Brasil ¹, Evelyne Vinet ², Christian Pineau ² and Sasha Bernatsky¹, ¹Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ²McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: The risks and benefits of long-term hydroxychloroquine (HCQ) use in systemic lupus erythematosus (SLE), versus tapering or stopping, remain uncertain. We aimed to identify predictors of…
Abstract Number: 1628 • 2019 ACR/ARP Annual Meeting
Lung Function Decline in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease in the SENSCIS Trial: Subgroup Analysis by Time Since First Non-Raynaud Symptom
Aryeh Fischer¹, Oliver Distler ², Dinesh Khanna ³, Yannick Allanore ⁴, Anna Maria Hoffmann-Vold ⁵, Gabriele Valentini ⁶, Toby Maher ⁷, Martin Aringer ⁸, Leslie Meng ⁹, Margarida Alves ¹⁰, Martina Gahlemann ¹¹, Manuel Quaresma ¹⁰ and Masataka Kuwana ¹², ¹University of Colorado School of Medicine, Denver, Colorado, USA, Denver, CO, ²Dept. of Rheumatology, University Hospital Zürich, Zürich, Switzerland, Zürich, Switzerland, ³Department of Medicine, University of Michigan, Ann Arbor, Michigan, USA, Ann Arbor, ⁴Dept. of Rheumatology A, Descartes University, APHP, Cochin Hospital, Paris, France, Paris, France, ⁵Department of Rheumatology, Oslo University Hospital, Oslo, Norway, Oslo, Norway, ⁶Dipartimento di Medicina di Precisione, II Policlinico U.O. Reumatologia, Napoli, Italy, Napoli, Italy, ⁷National Heart and Lung Institute, Imperial College London, UK and National Institute for Health Research Clinical Research Facility, Royal Brompton Hospital, London, UK, London, United Kingdom, ⁸Division of Rheumatology, Department of Medicine III, University Medical Center & Faculty of Medicine Carl Gustav Carus, TU Dresden, Dresden, Germany, Dresden, Germany, ⁹Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA, Ridgefield, ¹⁰Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim am Rhein, Germany, ¹¹Boehringer Ingelheim (Schweiz) GmbH, Basel, Switzerland, Basel, Switzerland, ¹²Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan, Bunkyo-ku, Tokyo, Japan
Background/Purpose: Interstitial lung disease (ILD) is a common and usually early manifestation of systemic sclerosis (SSc). Decline in lung function in patients with SSc-ILD is…
Abstract Number: 2841 • 2019 ACR/ARP Annual Meeting
A Double-Blind, Placebo-Controlled, Phase 2 Trial of a Novel Toll-Like Receptor 7/8/9 Antagonist (IMO-8400) in Dermatomyositis
Yoo Jung Kim¹, Elena Schiopu ², Katalin Dankó ³, Tahseen Mozaffar ⁴, Srinivas Chunduru ⁵, Kirstin Lees ⁶, Namita Goyal ⁴, David Fiorentino ⁷ and Kavita Sarin ⁷, ¹Stanford University School of Medicine, Redwood City, CA, ²Department of Rheumatology, University of Michigan, Ann Arbor, ³Department of Clinical Immunology, Medical Faculty, University of Debrecen, Debrecen, Hungary, ⁴Department of Neurology, University of California Irvine, Irvine, CA, ⁵Idera Pharmaceuticals, Inc., Cambridge, MA, ⁶Idera Pharmaceuticals, Inc., Cambridge, ⁷Department of Dermatology, Stanford University School of Medicine, Redwood City, CA
Background/Purpose: Dermatomyositis (DM) is a rare inflammatory disease of skin and muscle associated with characteristic skin findings, muscle weakness, interstitial lung disease, pruritus, and malignancies.…
Abstract Number: 62 • 2019 ACR/ARP Annual Meeting
Human Gingiva-derived Mesenchymal Stem Cells Are Therapeutic in Lupus Nephritis Through Targeting of CD39-CD73 Signaling Pathway
Song Guo Zheng¹, Julie Wang ², Junlong dang ³, Nancy Olsen ⁴ and Wael Jarjour ¹, ¹Ohio State College of Medicine, Columbus, OH, ²Ohio State University, columbus, ³Sun Yat-sen University, Guangzhou, ⁴Penn State University, Hershey, PA
Background/Purpose: Cell specific and cytokine targeted therapeutics have underperformed in systemic lupus erythematosus (SLE) in spite of numerous targets examined and clinical trials conducted. Mesenchymal…
Abstract Number: 1636 • 2019 ACR/ARP Annual Meeting
Effect of Anti-Topoisomerase I Antibody Status on Decline in Lung Function in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease: Data from the SENSCIS Trial
Maureen Mayes¹, Kristin Highland ², Martina Gahlemann ³, Aryeh Fischer ⁴, Ganesh Raghu ⁵, Mannaig Girard ⁶, Margarida Alves ⁷, Susanne Stowasser ⁷, Jörg Distler ⁸, Marco Matucci-Cerinic ⁹, Elizabeth Volkmann ¹⁰, Masataka Kuwana ¹¹ and Oliver Distler ¹², ¹Division of Rheumatology and Clinical Immunogenetics, University of Texas McGovern Medical School, Houston, Texas, USA, Houston, TX, ²Cleveland Clinic, Cleveland, Ohio, USA, Cleveland, OH, ³Boehringer Ingelheim (Schweiz) GmbH, Basel, Switzerland, Basel, Switzerland, ⁴University of Colorado School of Medicine, Denver, Colorado, USA, Denver, CO, ⁵University of Washington, Seattle, USA, Seattle, ⁶Boehringer Ingelheim France S.A.S., Reims, France, Reims, France, ⁷Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim am Rhein, Germany, ⁸Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany, Erlangen, Germany, ⁹University of Florence, Department of Medicine, Florence, Italy, Florence, Italy, ¹⁰University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, ¹¹Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan, Bunkyo-ku, Tokyo, Japan, ¹²Dept. of Rheumatology, University Hospital Zürich, Zürich, Switzerland, Zürich, Switzerland
Background/Purpose: The presence of anti-topoisomerase I antibody (ATA) in patients with systemic sclerosis (SSc) has been associated with a greater risk of developing interstitial lung…
Abstract Number: 102 • 2019 ACR/ARP Annual Meeting
Serine Arginine-Rich Splicing Factor 1 (SRSF1) Restrains IFN-γ and IL-17 Inflammatory Cytokine Production and Its Selective Deficiency in T Cells Exacerbates Experimental Autoimmune Encephalomyelitis (EAE) and Nephrotoxic Nephritis (NTN)
Takayuki Katsuyama¹, Kotaro Otomo ¹, Hao Li ², Michihito Kono ³, Nobuya Yoshida ¹, George Tsokos ¹ and Vaishali R. Moulton ¹, ¹Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, ²Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, ³Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Hokkaido, Japan
Background/Purpose: CD4 T helper 1 (Th1) and Th17 cells producing IFN-γ and IL-17 are aberrantly increased and contribute to inflammatory responses in autoimmune diseases including…
Abstract Number: 1643 • 2019 ACR/ARP Annual Meeting
Efficacy and Safety of Nintedanib in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease: Subgroup Analysis of the SENSCIS Trial by Corticosteroid Use
Madelon Vonk¹, Oliver Distler ², Daniel Furst ³, Eric Hachulla ⁴, Sindhu Johnson ⁵, Shervin Assassi ⁶, Leslie Meng ⁷, Manuel Quaresma ⁸, Margarida Alves ⁸, Emmanuelle Clerisme-Beaty ⁸ and Wim Wuyts ⁹, ¹Department of Rheumatology, Radboud University Medical Center, Nijmegen, The Netherlands, Nijmegen, Gelderland, Netherlands, ²Dept. of Rheumatology, University Hospital Zürich, Zürich, Switzerland, Zürich, Switzerland, ³University of California, Los Angeles, CA, ⁴Dept. of Internal Medicine and Clinical Immunology, Hôpital Claude Huriez, University of Lille, Lille, France, Lille, France, ⁵Toronto Scleroderma Program, Department of Medicine, Toronto Western and Mount Sinai Hospitals, University of Toronto, Toronto, Canada, Toronto, Canada, ⁶Division of Rheumatology and Clinical Immunogenetics, University of Texas McGovern Medical School, Houston, Texas, USA, Houston, TX, ⁷Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA, Ridgefield, ⁸Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim am Rhein, Germany, ⁹Unit for Interstitial Lung Diseases, Department of Respiratory Medicine, University Hospitals Leuven, Leuven, Belgium, Leuven, Belgium
Background/Purpose: In the SENSCIS trial in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD), nintedanib reduced the rate of decline in forced vital capacity (FVC)…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].